Broadly neutralizing HIV-1 antibodies (bNAbs) are neutralizing antibodies which neutralize multiple HIV-1 viral strains. [1] bNAbs are unique in that they target conserved epitopes of the virus, meaning the virus may mutate, but the targeted epitopes will still exist. [2] In contrast, non-bNAbs are specific for individual viral strains with ...

The recent development of HIV-1-specific potent broadly neutralizing antibodies (bNAbs) provides a new approach for preventing, treating, and potentially even eradicating HIV-1 infection. Due to their important features, including a longer half-life, excellent safety and engaging the host immune response, bNAbs are being strongly pursued and ...

Several anti-HIV-1 broadly neutralizing antibodies (bNAbs) with exceptional breadth and potency and targeting different HIV-1 envelope epitopes have entered clinical trials. bNAbs are being evaluated for their potential as long-acting alternatives to antiretrovirals in HIV-1 prevention and therapy, and for potential role in strategies aiming at ...

2023年10月5日 · By extensively incorporating glycans into the cognate epitope, bnAbs against HIV-1 Env avoid being as reliant on interactions with protein residues, which can vary in accessibility and mutate...

2022年8月12日 · These bnAbs targeted canonical bnAb epitopes on the HIV-1 trimer, including the V2 glycan, V3-glycan patch, CD4 binding site and fusion peptide, and bore a remarkable resemblance to human...

2024年2月1日 · Anti-HIV-1 bNAbs delay viral rebound, induce cellular immunity and have the capacity to reduce the viral reservoir in PWH. The efficacy of bNAb treatment is hampered by Env density, immune cell exhaustion, viral diversity, and antibody half-life.

2022年2月2日 · Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) are promising molecules for therapeutic or prophylactic interventions. Beyond neutralization,...

A type of antibody that can recognize and block many types of HIV from entering healthy cells. Broadly neutralizing antibodies (bNAbs) may also activate other immune cells to help destroy HIV-infected cells. Researchers are investigating whether bNAbs could be used to develop a therapeutic HIV vaccine.

2024年8月6日 · Many promising HIV cure strategies use broadly neutralizing antibodies, or bNAbs, which can neutralize a wide range of HIV variants, homing in on and binding to specific viral components, and then acting to destroy the virus by triggering an immune response. Several HIV bNAbs have been developed and tested to determine whether they can prevent ...

Passive immunization with a single bNAb offer a transient reduction in HIV-1 viremia–short lived but significant. Combination therapy of ≥2 bNAbs maintain viral suppression for a longer period of time and delay time to rebound after analytical treatment interruption (ATI) in individuals with antibody-sensitive strains.